Peritoneal Dialysis Catheter Infections

Introduction to Peritoneal Dialysis Catheter Infections

Peritoneal dialysis catheter infections are a common complication in patients undergoing peritoneal dialysis, and prompt treatment is essential to prevent serious consequences, as recommended by the Infectious Diseases Society of America 1

The Infectious Diseases Society of America recommends empiric antibiotic therapy for peritoneal dialysis catheter exit site infections, including vancomycin for gram-positive coverage and an agent for gram-negative coverage such as ceftazidime or gentamicin, with subsequent tailoring based on culture results 1
Vancomycin provides coverage for methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive organisms, with a recommended loading dose of 20 mg/kg followed by 500 mg during each subsequent dialysis session 1
Ceftazidime is recommended at a dose of 1 g IV after each dialysis session for gram-negative coverage 1
Empirical coverage should be based on local antimicrobial susceptibility patterns, according to the Infectious Diseases Society of America 1
For suspected fungal exit site infections, the Infectious Diseases Society of America recommends considering an echinocandin (caspofungin, micafungin, or anidulafungin) or fluconazole 1

The Infectious Diseases Society of America recommends antibiotic lock therapy with vancomycin, cefazolin, or gentamicin for persistent or recurrent exit site infections, with specific concentrations and durations of therapy 1
Recommended concentrations for antibiotic lock therapy are:
Antibiotic Concentration Heparin
Vancomycin 2.5-5.0 mg/mL 2500-5000 IU/mL
Cefazolin 5.0 mg/mL 2500-5000 IU/mL
Gentamicin 1.0 mg/mL 2500 IU/mL
1

The Infectious Diseases Society of America recommends continuing antibiotics for at least 2 weeks or until resolution of signs and symptoms for exit site infections, and longer therapy (3-4 weeks) may be required for infections associated with tunnel involvement 1
Extended duration of 4-6 weeks is recommended for persistent bacteremia, endocarditis, or suppurative thrombophlebitis, and 6-8 weeks for osteomyelitis, as suggested by the Clinical Infectious Diseases guidelines 1
Therapy should be continued for at least 2 days after resolution of signs and symptoms of infection, with longer therapy possibly required for complicated infections, as per standard medical practice 1

Vancomycin can be safely administered to patients on hemodialysis, but it requires specific dosing modifications and careful monitoring to ensure therapeutic efficacy while avoiding toxicity, as recommended by the Infectious Diseases Society of America 1
For hemodialysis patients, vancomycin should be administered during the last hour of the hemodialysis session or post-dialysis, and not before dialysis, to prevent significant drug removal and therapeutic failure 1
The American College of Physicians recommends measuring trough levels before the next dialysis session, with target pre-dialysis levels of 10-20 μg/mL for most infections and 15-20 μg/mL for severe infections 1
Other antibiotics, such as ceftazidime, cefazolin, and gentamicin, require modified dosing schedules, with doses administered after each dialysis session to prevent significant drug removal and ensure optimal therapeutic concentrations 1

Rapid infusion can cause "red man syndrome" (hypotension, flushing), and drug interactions should be monitored closely when combining vancomycin with other nephrotoxic agents, such as aminoglycosides or amphotericin B 1
The type of hemodialysis membrane used affects vancomycin clearance, with high-flux membranes removing more drug than low-flux membranes, as noted by the Clinical Infectious Diseases guidelines 1
Patients with renal impairment may accumulate cefepime despite dose adjustment, leading to neurotoxicity, and should be monitored for confusion, altered mental status, and myoclonus 1
Using nephrotoxic antibiotics, such as aminoglycosides, should be avoided when possible due to the risk of ototoxicity, as recommended by the Clinical Infectious Diseases guidelines 1
Serum drug concentrations should be monitored for antibiotics with narrow therapeutic ranges, such as vancomycin and aminoglycosides, as recommended by the American Journal of Respiratory and Critical Care Medicine and the Clinical Infectious Diseases guidelines 2, 1
Surveillance cultures should be obtained one week after completing antibiotic treatment if the catheter is retained, according to the Clinical Infectious Diseases guidelines 1
Monitor for vancomycin toxicity, including nephrotoxicity, which is defined as an increase in serum creatinine of 0.5 mg/dL or 150% from baseline, as recommended by the Clinical Infectious Diseases guidelines 3